Global Innovative Platforms Inc.

What they do

The company develops non-invasive breath and air analysis tools for animals and agriculture, using licensed devices called VOCAM Plus (Volatile Organic Chemical Air Monitor) and the FROG, which pair gas chromatography with AI software. Its stated first priority is a breath test to detect early-stage and mature heartworm infections in dogs, aiming to reduce the roughly six-month maturity window required by standard antigen blood tests. The FROG uses similar technology plus a collection wand for feed, water, soil, and air samples. The company licenses the VOCAM Plus and FROG for all animal and agricultural applications.

Revenue drivers

• Breath-based heartworm test (VOCAM Plus) — Lead development program for detecting early-stage and mature heartworm in dogs; no reported revenue contribution to date.
• FROG sample analysis — Licensed device for testing feed, water, soil, and air for animal and agricultural abnormalities; no reported revenue contribution to date.
• Sales and royalty income — Management states the company has 'begun to achieve sales and royalty income' as a subsequent event and describes those as limited; quarterly revenue of $30,000 (Dec 2025), $106,500 (Mar 2026) and $50,700 (Jun 2026) is the only reported revenue.

Recent performance

Annual revenue was $0.00 for 2021 through 2025, while quarterly revenue first appears at $30,000 for the quarter ended 2025-12-31, then $106,500 for 2026-03-31 and $50,700 for 2026-06-30. Net loss widened to $718,251 in fiscal 2025 from $136,197 in 2024. Operating cash flow was negative $560,740 in 2025 versus negative $87,378 in 2024. At 2026-06-30 the company reported total assets of $539,261, total liabilities of $7,791, shareholder equity of $531,470 and cash of $244,235. The 10-K discloses a retained deficit of approximately $1,250,000 as of September 30, 2025.

Strategy

Management's stated plan of operation is to obtain debt or equity financing to fund ongoing operating expenses and growth, issuing shares of common stock to create shareholder value. The company's initial technical priority is developing a breath test for early-stage and mature heartworm in dogs, with analysis of feed, water, soil, and air as additional animal and agricultural applications. It intends to seek trade association approvals and may pursue licensing or collaboration agreements. The company says it has no committed source of funds and may incur debt, which it does not currently contemplate.

Risks

• Going concern — The independent registered public accounting firm's report on the consolidated financial statements as of September 30, 2025 includes a going-concern explanatory paragraph describing substantial doubt about the company's ability to continue as a going concern.
• No committed funding — The company states it has no committed source of funds, needs substantial additional capital, and could fail in business if funds cannot be raised when needed.
• Dilution to existing holders — The company expects to raise money by issuing common stock, which management says can be expected to have a significant dilutive effect on the percentage held by current stockholders.
• Competitive disadvantage — Management states that established venture capital and financial concerns with greater financial and personnel resources and technical expertise may be developing alternatives, leaving the company at a significant competitive disadvantage.

Outlook

Management expects research, product launch, product development, and general and administrative expenses and operating losses to increase as it completes modifications and develops potential product candidates. It states future capital needs depend on the rate of progress in developing test results, the scope and costs of non-clinical studies and preclinical development, and the costs of seeking trade association approvals. The company has no committed source of funds and gives no timeline or revenue guidance.